Online inquiry

IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5077MR)

This product GTTS-WQ5077MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF2RA gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001161529.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1438
UniProt ID P15509
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5077MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12572MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NV-02
GTTS-WQ6462MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CT-P23
GTTS-WQ7975MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ15582MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ8904MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IGE25
GTTS-WQ10545MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3015014
GTTS-WQ12823MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMS721
GTTS-WQ9031MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMC RON-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW